VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN (Pelareorep) in Combination With Lenalidomide or Pomalidomide
Latest Information Update: 21 Nov 2022
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Pelareorep (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MUK eleven; VIRel
- 17 Nov 2022 Status changed from active, no longer recruiting to completed.
- 21 Jan 2020 Planned End Date changed from 1 May 2019 to 1 Oct 2021.
- 21 Jan 2020 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2021.